Clinical Trial Update: Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated abatacept as an adjuvant to peanut oral immunotherapy to promote remission in peanut allergy, and the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Abatacept (abatacept)

Snippet

Sponsor: Philippe Bégin | Conditions: Peanut Allergy | Phase 2 | Status: COMPLETED